Institute For Applied Cancer Science, Developing The Next Generation Of Oncology Agents For Targeted Patient Populations
Philip Jones,
Head of Drug Discovery, Institute for Applied Cancer Science. MD Anderson Cancer Center,
University of Texas MD Anderson Cancer Center
Institute for Applied Cancer Science (IACS) is a fully integrated small molecule drug discovery and development unit embedded within MD Anderson, leveraging the innovative academic science and clinical excellence for which MD Anderson is known. Its mission is to develop impactful new drugs, and advance these into early clinical proof-of-concept studies in targeted patient populations. The institute’s Bench at BedsideTM synergistic approach relies on three key components: A highly experienced team of professional drug discovery and development scientists. Real-time access to insights gained by the best physician scientists in the nation who treat over 100,000 cancer patients per year. Clinically informed, patient-oriented research programs that are focused on delivering impactful results to patients.
Officially established in November 2011, IACS has been operational since January 2012. Since then, the institute has built a state-of-the-art laboratory from the ground up, recruited a staff of talented scientists with proven track records in drug discovery and development, and developed a portfolio of projects that are being driven aggressively toward the clinic. The first of these, IACS-010759 an inhibitor of oxidative phosphorylation for the treatment acute myeloid leukemia, has completed GLP-toxicology studies and an Investigational New Drug (IND) application will be filed during 2Q16. The portfolio includes earlier programs in the areas of cancer metabolism, epigenetics, and signal transduction.
|
|
